Quality Control Co-op

Beam Therapeutics (NASDAQ:BEAM) downgraded by Wall Street Zen to "Strong Sell" August 16, 2026 Key points. * Wall Street Zen downgraded Beam Therapeutics to "Strong Sell" from "Sell," although the broader analyst consensus remains "Moderate Buy" with an average price target of $49. * Beam reported weaker-than-expected quarterly results, including an adjusted loss of $1.18 per share versus estimates of $1.11 and revenue of $0.49 million versus expectations of $16.37 million; revenue fell 94.2% year over year. * The stock opened at $26.75, below its 50-day average of $30.26, while insiders sold roughly $10.5 million worth of shares over the past 90 days. * MarketBeat previews top five stocks to own in September. Beam Therapeutics (NASDAQ:BEAM - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research report issued to clients and investors on Sunday. BEAM has been the subject of a number of other research reports. Sanford C. Bernstein lowered their price target on Beam Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a research report on Wednesday, May 13th. HC Wainwright reissued a "buy" rating on shares of Beam Therapeutics in a report on Monday, August 10th. Bank of America restated a "buy" rating and issued a $47.00 price objective on shares of Beam Therapeutics in a research note on Wednesday, July 8th. Tudor Pickering set a $39.00 target price on Beam Therapeutics in a report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Beam Therapeutics in a research report on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $49.00. Beam Therapeutics trading up 0.9%. NASDAQ BEAM opened at $26.75 on Friday. Beam Therapeutics has a 12-month low of $15.60 and a 12-month high of $38.26. The company has a fifty day simple moving average of $30.26 and a two-hundred day simple moving average of $28.80. The company has a current ratio of 14.57, a quick ratio of 14.57 and a debt-to-equity ratio of 0.09. The stock has a market cap of $2.76 billion, a P/E ratio of -31.10 and a beta of 2.23. Discover more Stocks & Bonds Stock average calculator Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.18) earnings per share for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.07). Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. The company had revenue of $0.49 million for the quarter, compared to analysts' expectations of $16.37 million. During the same period last year, the firm earned ($1.00) earnings per share. Beam Therapeutics's quarterly revenue was down 94.2% compared to the same quarter last year. On average, analysts forecast that Beam Therapeutics will post -4.49 earnings per share for the current year. Insider buying and selling at Beam Therapeutics. In other news, insider Fmr Llc sold 251,488 shares of the company's stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $35.26, for a total value of $8,867,466.88. Following the sale, the insider owned 854,583 shares in the company, valued at $30,132,596.58. This represents a 22.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Amy Simon sold 16,667 shares of the firm's stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $25.74, for a total value of $429,008.58. Following the sale, the insider directly owned 85,696 shares in the company, valued at approximately $2,205,815.04. This trade represents a 16.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 301,527 shares of company stock worth $10,468,500. 3.80% of the stock is owned by corporate insiders. Hedge funds weigh in on Beam Therapeutics. Several institutional investors have recently made changes to their positions in BEAM. Jones Financial Companies Lllp boosted its holdings in Beam Therapeutics by 55,780.0% during the first quarter. Jones Financial Companies Lllp now owns 33,528 shares of the company's stock worth $655,000 after buying an additional 33,468 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Beam Therapeutics by 10.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 438,529 shares of the company's stock worth $8,564,000 after acquiring an additional 42,609 shares during the period. Prudential Financial Inc. purchased a new stake in shares of Beam Therapeutics during the 2nd quarter worth about $201,000. New York State Common Retirement Fund boosted its stake in shares of Beam Therapeutics by 17.7% during the 2nd quarter. New York State Common Retirement Fund now owns 30,629 shares of the company's stock worth $521,000 after acquiring an additional 4,600 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Beam Therapeutics by 46.0% during the 2nd quarter. Invesco Ltd. now owns 128,874 shares of the company's stock worth $2,192,000 after acquiring an additional 40,583 shares in the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors. About Beam Therapeutics. Beam Therapeutics, Inc NASDAQ: BEAM is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need. Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Beam Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list. While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Beam one-ups Wave as both show promise of genetic editing for AATD. May 20, 2026 | While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets, analysts said that Beam might have the efficacy advantage as Wave's drug hits an efficacy "ceiling." Biopharma is gaining ground on alpha-1 antitrypsin deficiency, with recent readouts from Beam Therapeutics and Wave Life Sciences showing encouraging efficacy for DNA and RNA editing approaches. But Beam has walked away with an advantage this week, according to analysts. Beam is advancing a DNA editor called BEAM-302, which corrects the disease-causing genetic mutation by targeting a single base on the DNA. Phase 1/2 data showed that a single dose of the asset at 60-mg or greater slashed circulating levels of mutated alpha-1 antitrypsin (AAT) protein by around 80%, while facilitating the production of the healthy and normal version of the protein, according to data presented Monday at the American Thoracic Society (ATS) 2026 conference. Specifically, the treatment raised levels of AAT above the protective threshold of 11 μM. Both biomarker dynamics were robust and persisted through 12 months of follow-up, as per Beam's presentation. These data reinforce BEAM-302's "durable correction" of the pathologic genetic mutations, analysts at Jefferies told investors in a Tuesday note. The readout "continues to support best-in-disease profile for BEAM's AATD base editor," the analysts added. Aside from AAT levels, BEAM's data also showed significant reduction in neutrophil elastase levels across all patients, which according to Jefferies is a key functional biomarker. Beam plans to seek accelerated approval for BEAM-302 based on previous discussions with the FDA, according to a news release on Tuesday. In addition, the biotech expects to launch a pivotal cohort for the asset in the back half of 2026. Pfizer will be responsible for all global clinical and regulatory activities for Beam Therapeutics' liver-directed gene editor. February 26, 2026 Also at ATS 2026 is Wave, which is working on a subcutaneous RNA editor called WVE-006. The investigational oligonucleotide therapy works by correcting the base mutation in the RNA molecule that is translated to the mutant AAT protein. Data from the Phase 1b/2a RestorAATion-2 study showed that a single dose of WVE-006 resulted in an up to 59.1% reduction in the mutated and toxic form of AAT, according to a news release on Tuesday. This effect increased to 70.5% for multiple doses. At the same time, Wave's asset restored the expression of wild-type AAT, the biotech said. Despite these data, Leerink Partners considered Wave's asset underwhelming by comparison, writing on Tuesday that the readout "falls short of the bar set by BEAM, in our view, and positions BEAM for first-mover advantage in both pivotal enrollment and eventual launch." In particular, Wave's results suggests that WVE-006 "may be hitting a ceiling on AAT biomarkers," Jefferies said in its note, pointing to the asset's diminishing improvements even at multiple ascending doses. Leerink agreed: "even with multi-dose therapy, WVE lags on key efficacy," the analysts wrote. Like Beam, Wave is banking on an accelerated pathway for WVE-006, for which regulatory feedback should come mid-2026, according to the biotech's Tuesday release.

ADAR1 Capital Management has taken a new $40.13 million position in Beam Therapeutics, purchasing 1,446,375 shares during the first quarter of 2026, according to an SEC filing dated 15 May. The position represented 2.03% of the fund's reportable assets as of 31 March. Beam Therapeutics, a biotechnology company developing precision genetic medicines using base editing technology, focuses on treating serious genetic disorders including sickle cell disease and beta thalassemia. The company generated $164.01 million in trailing twelve-month revenue but reported a net loss of $65.04 million. As of 15 May 2026, Beam shares traded at $27.93, up 61.9% year-on-year, outperforming the S&P 500 by 36.7 percentage points. The company's market capitalisation stood at $2.87 billion.